Newsletter Signup | Join Community
Classification of Non-Hodgkin Lymphomas is necessary to determine treatment.
Treatment of Mantle Cell Lymphoma: ASH 2019 Update: Imbruvica-Rituxan promising - Initial reports on CAR T cell therapy
Connect with Others at Top Cancer Centers - Second Opinion Options...
Update for recurrent B-cell NHL treated with Yescarta CAR - T cells - side effects are not insignificant.
What you need to know about CAR T cell therapy for the treatment of cancer - update from ASH 2019
FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
MOR208 targeting the CD19 B cell antigen is promising treatment of advanced lymphomas
Research studies help non-Hodgkin’s lymphoma patients understand their risk of developing a new (secondary) cancer.
How long have people been on watch and wait before they needed treatment ?
Rituxan Maintenance; has your doctor recommended it every 2 or every 3 months?
Long-Term Follow-Up Indicates Survival with Addition of Rituxan® to CHOP in NHL
Curious is others with celiac disease have develeoped lymphoma? https://mavendoctors…